An expert panel during the International Society for Pharmacoeconomics and Outcomes Research’s (ISPOR) meeting in New Orleans discussed a number of innovative payment models for tackling some key cost hurdles involving new, transformative therapies.
The National Pharmaceutical Council (NPC) in a blog post highlighted some of the key takeaways from the panel discussion.
“Given the large upfront payment, the multiple layers and players of the payment ecosystem, including self-insured employers and payers and reinsurers, need to be considered,” the blog post states.
To read the full post on NPC’s website, click here.
